BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 953 filers reported holding BAXTER INTL INC in Q2 2014. The put-call ratio across all filers is 0.79 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2017 | $291,000 | -47.3% | 4,500 | -48.9% | 0.16% | -34.1% |
Q3 2017 | $552,000 | -5.0% | 8,800 | -8.3% | 0.25% | -9.9% |
Q2 2017 | $581,000 | +16.7% | 9,600 | 0.0% | 0.27% | +14.7% |
Q1 2017 | $498,000 | +6.9% | 9,600 | -8.6% | 0.24% | +2.1% |
Q4 2016 | $466,000 | -6.8% | 10,500 | 0.0% | 0.23% | -9.0% |
Q3 2016 | $500,000 | +5.3% | 10,500 | 0.0% | 0.26% | +1.2% |
Q2 2016 | $475,000 | +10.2% | 10,500 | 0.0% | 0.25% | +8.1% |
Q1 2016 | $431,000 | +95.0% | 10,500 | +81.0% | 0.23% | +87.2% |
Q4 2015 | $221,000 | -39.3% | 5,800 | +11.5% | 0.12% | -34.9% |
Q2 2015 | $364,000 | +4.3% | 5,200 | +2.0% | 0.19% | +6.1% |
Q1 2015 | $349,000 | -6.7% | 5,100 | 0.0% | 0.18% | -10.8% |
Q4 2014 | $374,000 | -25.5% | 5,100 | -27.1% | 0.20% | -33.0% |
Q3 2014 | $502,000 | -0.8% | 7,000 | 0.0% | 0.30% | +2.7% |
Q2 2014 | $506,000 | -1.7% | 7,000 | 0.0% | 0.30% | -7.8% |
Q1 2014 | $515,000 | – | 7,000 | – | 0.32% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Point | 36,000,000 | $2,658,240,000 | 18.52% |
SECTOR GAMMA AS | 721,058 | $53,243,000 | 8.85% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 2,747,061 | $202,843,000 | 5.38% |
Veritas Asset Management LLP | 8,852,005 | $653,632,000 | 5.36% |
Knowledge Leaders Capital, LLC | 79,384 | $5,862,000 | 4.39% |
HealthCor Management, L.P. | 1,800,000 | $132,912,000 | 4.22% |
Progressive Investment Management Corp | 79,282 | $5,854,000 | 3.78% |
13D Management LLC | 200,318 | $14,791,000 | 3.77% |
ARGENT CAPITAL MANAGEMENT LLC | 1,288,236 | $95,123,000 | 3.42% |
Chiron Investment Management, LLC | 612,787 | $45,248,000 | 3.12% |